Secondary (functional) mitral regurgitation — chronic
Ischaemic/functional MR · Cardiac
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Secondary mitral regurgitation results from left-ventricular dilatation or regional dysfunction tethering a structurally normal valve, commonly after MI or in dilated cardiomyopathy. Guideline-directed heart failure therapy is the foundation, with transcatheter repair benefiting selected patients.
Red flags
- Acute pulmonary oedema
- Rapidly worsening symptoms despite optimal therapy
- Haemodynamic instability (consider acute MR)
- Progressive LV dilatation and falling EF
- Severe pulmonary hypertension
Assessment
Differential diagnosis
- Primary (degenerative) mitral regurgitation
- Ischaemic functional MR
- Atrial functional MR (from AF/LA dilatation)
- Dilated cardiomyopathy-related MR
- Acute MR (papillary rupture)
- Mixed valve disease
Investigations
- Transthoracic echo (EROA, regurgitant volume, LV size/function)
- Transoesophageal echo for mechanism and intervention planning
- Ischaemia/viability assessment where relevant
- NT-proBNP
- ECG and rhythm assessment
- Right-heart catheterisation if pulmonary hypertension suspected
Management
- Confirm MR is secondary and quantify severity
- Establish the mechanism: ventricular (ischaemic/dilated) versus atrial
- Optimise and maximise guideline-directed heart failure therapy first
- Add cardiac resynchronisation therapy if indicated — it can reduce functional MR
- Revascularise where viable ischaemic myocardium is contributing
- Reassess MR severity after therapy optimisation (it often improves)
- Refer persistent severe symptomatic secondary MR for heart-team evaluation
- Offer transcatheter edge-to-edge repair to appropriately selected patients (per COAPT-type criteria)
- Consider surgery when combined with other cardiac surgery
- Manage atrial fibrillation and anticoagulate as indicated
- Treat atrial functional MR by addressing AF and LA remodelling
- Arrange heart-failure and valve-clinic follow-up
Drugs & doses
Sacubitril/valsartan 49/51 mg PO BD, titrate to 97/103 mg BD
Bisoprolol 1.25-10 mg PO OD titrated
Eplerenone 25-50 mg PO OD (or spironolactone)
Dapagliflozin 10 mg PO OD
Furosemide 40-120 mg PO OD for congestion
Disposition
Heart-failure and valve multidisciplinary team; transcatheter repair in selected patients after optimal medical therapy.
Complications & pitfalls
- Progressive heart failure
- Pulmonary hypertension
- Atrial fibrillation
- Recurrent hospitalisation
- Procedural complications of valve intervention
Exam pearls
- Guideline-directed medical therapy is the cornerstone — reassess MR after optimisation
- Transcatheter edge-to-edge repair benefits a specific 'disproportionate MR' phenotype (COAPT)
- CRT can reduce functional MR by improving LV geometry
- The valve is structurally normal — the ventricle (or atrium) is the problem
- Surgery alone for ventricular functional MR has not consistently improved survival
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.